Advertisement
Molecular Pathways

Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance

Alfonso Quintás-Cardama and Srdan Verstovsek
DOI: 10.1158/1078-0432.CCR-12-0284 Published April 2013

Abstract

Aberrant activation of the JAK/STAT pathway has been reported in a variety of disease states, including inflammatory conditions, hematologic malignancies, and solid tumors. For instance, a large proportion of patients with myeloproliferative neoplasms (MPN) carry the acquired gain-of-function JAK2 V617F somatic mutation. This knowledge has dramatically improved our understanding of the pathogenesis of MPNs and has facilitated the development of therapeutics capable of suppressing the constitutive activation of the JAK/STAT pathway, now recognized as a common underlying biologic abnormality in MPNs. Ruxolitinib is an oral JAK1 and JAK2 inhibitor that has recently been approved for the treatment of myelofibrosis and has been tested against other hematologic malignancies. A series of agents with different specificities against different members of the JAK family of proteins is currently undergoing evaluation in clinical trials for patients with MPNs, lymphoma, and solid tumors such as breast or pancreatic cancer. Despite the significant clinical activity exhibited by these agents in myelofibrosis, some patients fail to respond or progress during JAK kinase inhibitor therapy. Recent reports have shed light into the mechanisms of resistance to JAK inhibitor therapy. Several approaches hold promise to overcome such resistance. Clin Cancer Res; 19(8); 1933–40. ©2013 AACR.

Disclosure of Potential Conflicts of Interest

A. Quintás-Cardama is a consultant/advisory board member of Incite. S. Verstovsek received research support for conduct of clinical studies with JAK inhibitors from Incyte, Astrazeneca, SBIO, Lilly Oncology, Exelixis, NS Pharma, Bristol Myers Squibb, YM Biosciences, and Cephalon.

CME Staff Planners Disclosures

The members of the planning committee have no real or apparent conflict of interest to disclose.

Learning Objectives

On completion of this activity, the participant should have a better understanding of the role of the JAK/STAT pathway in cancer, the new development of therapeutics targeting JAK kinases, and the mechanisms of resistance to JAK inhibitor therapy.

Acknowledgment of Financial or Other Support

This activity does not receive commercial support.

Background

The JAK/STAT pathway is critical in normal hematopoiesis. The JAK family of kinases includes JAK1, JAK2, JAK3, and TYK2. Homozygous germline deletion of JAK2 alleles in mice results in embryonic lethality due to ineffective erythropoiesis (1, 2). JAK kinases are activated through tyrosine phosphorylation of the cytoplasmic domains of cytokine receptors upon cytokine binding (3). Erythropoietin, thrombopoietin, granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5, among others, signal through JAK2, whereas IL-6, IL-10, IL-11, IL-19, IL-20, IL-22, and IFN-γ signal through both JAK1 and JAK2. JAK2 activation promotes recruitment to the receptor complex of the transcription factors STAT3 and STAT5 (3). JAK2-mediated STAT phosphorylation leads to the formation of stable homodimers and heterodimers, which leads to their nuclear translocation (Fig. 1). Once in the nucleus, STAT molecules bind specific promoter DNA sequences that result in the transcription of genes that regulate cell proliferation, differentiation, and apoptosis (e.g., Bcl-xL, cyclin D1, and PIM1; refs. 3, 4).

Figure 1.
Figure 1.

JAK/STAT pathway in MPNs. Upon cytokine binding, JAK2 molecules are recruited and activated by cytokine receptors, which results in phosphorylation of downstream signaling pathways such as phosphoinositide 3-kinase (PI3K), RAS, and STAT3/5. STAT heterodimers and homodimers translocate to the nucleus and bind cognate DNA sequences at the promoter regions of genes involved in proliferation and apoptosis. In the presence of JAK2V617F mutations, the JAK/STAT pathway is constitutively activated. JAK2 inhibitors abrogate the JAK/STAT pathway through the inhibition of the kinase activity of JAK2V617F kinase. The activity of the JAK2/STAT pathway is negatively regulated by SOCS1 and LNK. Recently, JAK2 and JAK2V617F kinase have been shown to localize to the nucleus of hematopoietic precursors where they phosphorylate histone H3 (H3Y41), thus preventing its binding to the repressor HP1α. The latter results in increased expression of the oncogene lmo2. These effects are reversible upon exposure to JAK2 inhibitors. JAK2V617F also binds and phosphorylates the arginine methyltransferase PRMT5, which hampers its interaction with methylosome protein 50 (MEP50), thus decreasing global arginine methylation of histones H2A and H4. The figure is modified from Quintás-Cardama and colleagues (59).

The myeloproliferative neoplasms (MPN) polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (MF) are clonal malignancies that arise from hematopoietic stem or progenitor cells and are characterized by unchecked proliferation of terminally differentiated myeloid cells (5). Despite certain idiosyncratic features, these MPNs have remarkable phenotypic and clinical commonalities, such as their proclivity to develop thrombotic and hemorrhagic complications and to progress to acute myeloid leukemia (AML; refs. 6–9). The molecular pathogenesis of MPNs remained elusive for decades, which has proven detrimental for the development of effective therapies, particularly for primary myelofibrosis, an MPN associated with high morbidity and mortality. In fact, none of the standard approaches for the treatment of MPNs (e.g., hydroxyurea, growth factors, splenectomy) has been shown to improve the survival of patients with primary myelofibrosis, which is estimated to be only about 5 years (10). Allogeneic stem cell transplantation has proved the only curative strategy in myelofibrosis but at the expense of a very high morbidity and mortality (11, 12). A nexus linking polycythemia vera, essential thrombocythemia, and myelofibrosis was revealed in 2005 with the discovery of a recurrent somatic point mutation in the pseudokinase domain of the Janus kinase 2 (JAK2) gene, which is present in a large proportion of patients with these MPNs. In addition, overactivation of the JAK/STAT pathway with or without JAK protein mutations has been reported in subsets of patients with certain solid tumors and hematologic malignancies. Somatic mutations in the JAK3 gene, including JAK3A572V, JAK3V722I, and JAK3P132T, and chimeric fusion transcripts involving JAK2, such as ETV6-JAK2, PCM1-JAK2, TEL-JAK2, and PCR-JAK2, have been reported in acute lymphoblastic (ALL) and AMLs (13, 14), as well as in multiple myeloma and non–Hodgkin lymphoma (NHL; ref. 15). JAK2R683 mutations have been reported in 7% of patients with high-risk B-cell ALLs and in 25% of cases of ALLs associated with Down syndrome (16–18). Overall, mutated JAK1, JAK2, and JAK3 proteins have been reported in approximately 10% of children with high-risk Philadelphia chromosome–negative ALLs (16) and anecdotally in AMLs (19–22). Activation of the JAK/STAT pathway is also present in chronic myeloid leukemia, in which inhibition of JAK2-mediated extrinsic survival signals restores sensitivity to BCR–ABL1 kinase inhibitors (23). JAK2 mutations have not been reported in NHLs, but the JAK/STAT pathway is frequently activated through JAK2 amplification via 9p24 copy number gain, which has been reported in 30% to 50% of cases of Hodgkin lymphoma and primary mediastinal B-cell lymphoma (24–26). In solid tumors, persistent phosphorylation of STAT1, STAT3, and STAT5 has been shown in breast, lung, and head and neck cancers, mediated by an increase in cytokine levels, in both an autocrine and paracrine manner, and by enhanced expression of cytokine receptors (27).

Molecular biology of the JAK/STAT pathway

In 2005, a gain-of-function acquired somatic mutation was described in the JAK2 gene in a significant proportion of patients with MPNs (28–32). JAK2V617F mutation arises from a single base G→T transversion in the pseudokinase domain of JAK2, resulting in a valine-to-phenylalanine substitution at codon 617 that putatively disrupts the autoinhibitory activity of the pseudokinase domain (JH2), thus constitutively activating the kinase domain (JH1) of JAK2 (33). As a consequence, hematopoietic cells carrying the JAK2V617F mutation exhibit cytokine hypersensitivity and cytokine-independent growth (34). JAK2V617F is present in 50% to 60% of patients with primary myelofibrosis or essential thrombocythemia and in more than 95% of those with polycythemia vera (28, 31). Although most bone marrow erythroid colonies obtained from patients with essential thrombocythemia bear JAK2 alleles that are either wild type or JAK2V617F heterozygous (3, 30, 31), virtually all patients with polycythemia vera carry JAK2V617F homozygous erythroid colonies as a result of uniparental disomy at the JAK2 locus (3, 30, 31). Several somatic gain-of-function mutations at exon 12 of JAK2 have been described in patients with polycythemia vera without the JAK2V617F mutation (35–38). Therefore, JAK2 mutations are present virtually in all patients with polycythemia vera. In addition, somatic mutations at exon 10 of the MPL gene, which encodes the transmembrane–juxtamembrane junction of MPL (W515L/K/A), are present in approximately 5% of patients with essential thrombocythemia or myelofibrosis, resulting in downstream signaling activation similar to that mediated by JAK2V617F (39–42).

LNK, a negative regulator of JAK/STAT signaling, has been found mutated in a subset of patients with MPNs, providing a mechanism of JAK/STAT activation in patients carrying wild-type JAK2 alleles (43). The presence of the JAK2V617F mutation in CD34+CD38− hematopoietic stem cells in all mature blood cell lineages of patients with MPNs (44–46) disrupts the autoregulatory activity of JH2, resulting in constitutive activation of the JAK2/STAT pathway and cell growth in the absence of cytokine stimulation (29, 31). JAK2V617F also activates the phosphoinositide 3-kinase (PI3K)/Akt/mTOR/forkhead transcription factors (FoxO) signaling proteins as well as the Ras pathway that promotes survival and proliferation, thereby preventing apoptosis of hematopoietic progenitor cells (3). Furthermore, enforced expression of JAK2V617F in human hematopoietic stem cells and myeloid progenitors steers differentiation toward the erythroid lineage, which is accompanied by decreased expression of PU.1 and enhanced expression and phosphorylation of GATA-1 (47–49). JAK2 signaling is negatively regulated by suppressor of cytokine signaling (SOCS) proteins, most importantly SOCS1. JAK2 inhibitor treatment (50, 51), or overexpression of a dominant-negative form of STAT5, abrogates the growth of polycythemia vera erythroid progenitors in vitro (52), thus implicating JAK2 in the pathogenesis of MPNs and providing the rationale to use JAK2 inhibitors for the treatment of patients with MPNs.

The role of JAK2V617F in the pathogenesis of MPNs has been validated in transgenic mouse models of JAK2V617F-driven disease in which low levels of JAK2V617F rendered an essential thrombocythemia-like phenotype, whereas high levels were associated with a polycythemia vera–like phenotype (53, 54). A mouse model in which JAK2V617F is expressed from its endogenous promoter displays a phenotype resembling human polycythemia vera and is transplantable to recipient mice (55), indicating that the resulting JAK2V617F-induced MPN is cell autonomous in nature. In this model, JAK2 inhibitor therapy ameliorated the phenotype but failed to fully eradicate MPN-initiating cells (55). To definitely confirm these results, a similar knockin approach in a different mouse model produced a phenotype characterized by erythrocytosis, leukocytosis, thrombocytosis, splenomegaly, reduced serum erythropoietin, and erythropoietin-independent erythroid colonies in both heterozygous and homozygous mice for the mutation, although most significantly in the latter (56).

STAT-independent JAK2 oncogenic signaling

In addition to modulating cytokine-mediated signaling via activation of STAT transcription factors, JAK2 kinase also renders oncogenic effects through epigenomic alterations (Fig. 1). Wild-type JAK2 as well as JAK2V617F proteins have been found in the cytoplasm and the nucleus of human leukemic cell lines and primary CD34+ hematopoietic progenitors (57). In the nucleus, JAK2 phosphorylates histone H3 at tyrosine 41 (H3Y41). The levels of phosphorylated H3Y41 correlate with JAK2 activity in vivo. Notably, JAK2 appears to be the only kinase responsible for H3Y41 phosphorylation as treatment with JAK2 inhibitors such as TG101209 or AT9283 abrogates H3Y41 phosphorylation in the nucleus (57). In Drosophila, JAK2 kinase activation disrupts the binding of the transcriptional repressor heterochromatin protein 1 alpha (HP1α) from chromatin. Interestingly, the affinity of HP1α for histone H3 is dependent on the phosphorylation status of H3Y41. H3Y41 phosphorylation decreases the affinity of H3 to HP1α. JAK2 inhibitors abrogate H3Y41 phosphorylation and enhance chromatin-bound HP1α in cells, thus repressing HP1α-regulated genes. Most JAK2-regulated genes do not contain a predicted STAT5-binding site, suggesting that these genes are regulated by signals other than JAK2/STAT5 pathway (57). One such gene is lmo2, which is involved in normal hematopoiesis and in leukemogenesis. JAK2 inhibitors decrease H3Y41 phosphorylation and promote HP1α binding at the lmo2 transcriptional start site, which results in downregulation of lmo2 expression. Therefore, the JAK2/H3Y41/HP1α pathway interconnects JAK2 kinase activity, histone phosphorylation, aberrant gene expression, and genome instability.

Recently, JAK2V617F was found to bind and phosphorylate the protein arginine methyltransferase 5 (PRMT5) much more efficiently than JAK2 (58). Such modification impairs the activity of PRMT5 and impedes its interaction with methylosome protein 50 (MEP50). The net result is a marked decrease in global arginine methylation of histones H2A and H4, both targets of MEP50. The gain-of-function activities described above represent noncanonical functions of JAK2V617F that contribute to tumorigenesis through epigenomic alterations (58).

Clinical–Translational Advances

Clinical trials with JAK tyrosine kinase inhibitors

Various JAK2 inhibitors have been tested in clinical trials for patients with intermediate- or high-risk myelofibrosis. An account of the in vitro activity of the agents that are further in clinical development is presented in Table 1 (59). Ruxolitinib potently inhibits the phosphorylation of JAK1, JAK2, JAK2V617F, STAT5, and ERK1/2 in vitro, which is coupled with induction of apoptosis (60). In a phase I/II study in 153 patients with myelofibrosis, the dose-limiting toxicity (DLT) was grade 4 thrombocytopenia (61). Ruxolitinib markedly reduced the levels of multiple fibrogenic and pro-inflammatory cytokines (e.g., IL-6, IL-8, TNF-α) regardless of JAK2 mutational status, suggesting that the clinical activity of ruxolitinib may be partly due to its JAK1 inhibitory activity (61). In the phase III study COMFORT-I, patients with myelofibrosis were randomized to placebo (n = 154) or ruxolitinib (n = 155). The primary endpoint, ≥35% volumetric reduction of the spleen at week 24, occurred in 41.9% versus 0.7% (P < 0.001) of patients receiving ruxolitinib or placebo, respectively (62). Similarly, ruxolitinib improved total symptom score by at least 50% in 45.9% of patients versus 5.3% with placebo (62). After a median follow-up of 24 months, fewer deaths were observed in the ruxolitinib arm (27 vs. 41 for placebo; P = 0.028; ref. 63). The most common grade 3 and 4 adverse events with ruxolitinib were anemia (45.2% vs. 19.2% with placebo) and thrombocytopenia (12.9% vs. 1.3% with placebo; ref. 62). COMFORT-II randomized patients with intermediate- or high-risk myelofibrosis 2:1 to ruxolitinib (n = 146) or best available therapy (BAT; n = 73; ref. 64). Reduction of spleen volume ≥35% at 48 weeks occurred in 28.5% of patients with ruxolitinib and 0% in those receiving BAT (P < 0.001). After a median follow-up of 28 months, the percentage of deaths was lower in the ruxolitinib arm (14% vs. 22% for BAT; P = 0.041; ref. 65). In November 2011, ruxolitinib was approved by the U.S. Food and Drug Administration for treating intermediate- and high-risk myelofibrosis based on the results of the COMFORT trials.

View this table:
Table 1.

Activity of selected JAK inhibitors currently being evaluated in clinical trials

SAR302503 (formerly TG101348) inhibits JAK2 and JAK2V617F preferentially over other members of the JAK family of kinases, and only 3 (JAK2, FLT3, and RET) among 223 kinases tested were inhibited by SAR302503 with an IC50 <50 nmol/L (51). In a phase I study (66), the maximum tolerated dose (MTD) of SAR302503 was 680 mg/d. Grade 3 and 4 anemia, thrombocytopenia, and neutropenia occurred in 35%, 24%, and 10% of patients, respectively. After 12 cycles, 47% of patients in the MTD cohort achieved a ≥50% decrease in splenomegaly that was sustained for ≥8 weeks (66, 67). In a phase II study, patients were randomized to SAR302503 at 300, 400, or 500 mg daily. Reductions of spleen volume ≥35% at the end of cycle 3 were dose-dependent: 30%, 50%, and 64% for the 300-, 400-, and 500-mg daily groups, respectively, which correlated with inhibition of STAT3 phosphorylation (68). A phase III placebo-controlled study of SAR302503 in myelofibrosis is under way.

CYT387 is a JAK1/2 inhibitor that is being studied in a phase I/II study that includes 166 patients with myelofibrosis in the core portion of the study and 120 patients in the multicenter extension portion (69). The MTD was determined to be 300 mg/d, and the DLT was reached at 400 mg/d (70). After a median follow-up of 16.9 months, 13% of patients in the core study had an increase in hemoglobin level of at least 2 g/dL, and 37% had durable reduction in spleen length by palpation of at least 50%. On the basis of these encouraging results, the dose of 300 mg/d was selected for a phase III study that will be conducted as a strategy for the approval of this agent.

Pacritinib is a selective JAK2 inhibitor that has been tested in a phase II study involving 34 patients with myelofibrosis. Eleven (32%) patients had ≥35% reduction in spleen volume at 24 weeks (71). The most frequent toxicity was gastrointestinal, although it was generally mild and manageable, without significant myelosuppression (71). Two patients had clinical improvement of hemoglobin, and a significant proportion of patients had improvement of constitutional symptoms. A phase III study of pacritinib for patients with low platelet levels is being planned. Of note, pacritinib has been recently tested in a phase I study in 34 patients with relapsed/refractory Hodgkin lymphoma or NHL. Pacritinib was well-tolerated, and the MTD was not reached. Three patients had a partial response, and 15 had stable disease (72).

Overcoming JAK2 inhibitor resistance

Although JAK2 inhibitors have proved effective in patients with MPNs, a fraction of them will have suboptimal responses and overall none will experience significant reductions in JAK2V617F allele burden, indicating persistence of the malignant clones. It has been recently shown that such resistance to JAK2 inhibitor therapy is not mediated by secondary mutations in the JAK2V617F kinase. Rather, it is the consequence of the reactivation of the JAK/STAT pathway via heterodimerization of activated JAK2 and JAK1 or TYK2 that promotes resistance to JAK2 inhibitor–induced apoptosis (73). Chronic JAK2 inhibitor therapy results in stabilization of activated JAK2 and an increase in JAK2 mRNA expression, which facilitates the formation of heterodimers. Notably, removal of JAK2 inhibitor treatment results in resistant JAK2V617F-positive cell resensitization, suggesting that patients resistant to JAK2 inhibitors might respond to retreatment with the same JAK2 inhibitor or with others after a period of therapy discontinuation.

It has been shown that Hsp90 inhibitors or histone deacetylase inhibitors (HDACi) promote JAK2 degradation, which suggests a potential role for these agents in the treatment of JAK2 inhibitor–resistant MPNs (74, 75). Treatment of cells with persistent JAK2 inhibitor–induced JAK/STAT pathway activation with the Hsp90 inhibitor PU-H71 resulted in JAK2 degradation and decreased activation of the JAK/STAT pathway. The combination of panobinostat, which is known to inhibit the chaperone function of Hsp90 and promote proteasomal degradation of JAK2V617F, with the JAK2 inhibitor TG101209 synergistically induced apoptosis of HEL and Ba/F3-JAK2V617F cells and exerted greater cytotoxicity against primary CD34+ MPN cells than normal CD34+ hematopoietic progenitor cells (74). Murine models suggest that the combination of a HDACi such as panobinostat with ruxolitinib exhibits markedly improved anticancer activity compared with either agent alone in a JAK2V617F bone marrow transplantation mouse model of MPN (76).

An alternative strategy to eliminate resistance cells is the use of type II JAK2 inhibitors, such as BBT-594, which, unlike available JAK2 inhibitors, retain the ability to bind the inactive conformation of JAK2 and inhibit signaling emanating from mutant JAK2 in persistent JAK2V617F-positive cells.

In addition to cell-autonomous mechanisms of resistance, extrinsic humoral factors secreted by the bone marrow microenvironment have been shown to protect MPN clones from JAK2 inhibitor therapy. We have recently shown the potent growth suppression exerted by the JAK2 inhibitor atiprimod on murine FDCP-EpoRV617F and JAK2V617F-positive human SET-2 cells while causing minimal effects on stromal cells (77). However, culture of JAK2V617F-positive cells on monolayers of stromal cells markedly impaired the ability of atiprimod to inhibit the phosphorylation of the JAK2/STAT3/5 pathway and the proliferation of JAK2V617F-positive cells. These effects are not due to direct interactions between the malignant clones and the marrow stroma. Rather, they are mediated by a network of cytokines secreted by the stromal cells, such as IL-6, fibroblast growth factor, and IP-10 (77). Blocking such cytokines with specific neutralizing antibodies restored JAK2 inhibitor sensitivity, thus showing the importance of non–cell autonomous mechanisms of resistance against JAK2 inhibitors and the therapeutic potential of strategies targeting the bone marrow niche in MPNs.

Conclusions

Our understanding of the pathogenesis of MPNs has markedly improved in recent years. The critical importance of the JAK2V617F mutation has been validated in vitro as well as in vivo by means of murine models of MPNs driven by JAK2V617F. In addition, several novel mutations in other genes have since been described in patients with MPNs, including TET2 mutations, which can appear before the acquisition of JAK2V617F, or IKZF1, EZH2, and ASXL1, which appear to contribute to leukemic transformation (78).

Despite this wealth of information, several questions remain to be answered. First, the precise role of other mutated alleles in the pathogenesis of MPNs and potentially in the resistance to JAK kinase inhibitor therapy remains unknown. Second, mounting data indicate that mutant JAK2 induces epigenetic deregulation, which, coupled with the fact that some of the mutant alleles found in MPNs outside of the JAK2 locus encode important epigenetic regulators, suggests the possibility that therapeutic epigenetic modifiers might play a role in the management of these malignancies. Third, available evidence indicates that JAK2 inhibition produces very modest effects on JAK2V617F allele burden, cytopenias, and bone marrow fibrosis, which suggests that such an approach alone cannot significantly correct the malignant phenotype observed in patients with myelofibrosis. Fourth, the therapeutic role of JAK1 inhibition versus JAK2 inhibition in myelofibrosis is unclear. Ongoing studies with selective JAK1 inhibitors in this context are eagerly awaited. Finally, it remains to be seen whether the synergism observed in vitro between JAK2 inhibitors and other therapeutics will translate into efficacious therapeutic strategies in patients exhibiting resistance to JAK2 inhibitor therapy and whether the treatment paradigm of JAK2 inhibition can be successfully extended to other malignancies, hematologic or otherwise, with deregulation of the JAK/STAT pathway.

Authors' Contributions

Conception and design: A. Quintas-Cardama, S. Verstovsek

Development of methodology: A. Quintas-Cardama, S. Verstovsek

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A. Quintas-Cardama, S. Verstovsek

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A. Quintas-Cardama, S. Verstovsek

Writing, review, and/or revision of the manuscript: A. Quintas-Cardama, S. Verstovsek

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S. Verstovsek

Study supervision: S. Verstovsek

Grant Support

S. Verstovsek received research support for conduct of clinical studies with JAK inhibitors from Incyte, Astrazeneca, SBIO, Lilly Oncology, Exelixis, NS Pharma, Bristol Myers Squibb, YM Biosciences, and Cephalon.

  • Received October 19, 2012.
  • Revision received December 20, 2012.
  • Accepted January 7, 2013.

References

  1. 1.↵
    1. Neubauer H,
    2. Cumano A,
    3. Muller M,
    4. Wu H,
    5. Huffstadt U,
    6. Pfeffer K
    . Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998;93:397–409.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Parganas E,
    2. Wang D,
    3. Stravopodis D,
    4. Topham DJ,
    5. Marine JC,
    6. Teglund S,
    7. et al.
    Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998;93:385–95.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Levine RL,
    2. Pardanani A,
    3. Tefferi A,
    4. Gilliland DG
    . Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673–83.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Silva M,
    2. Richard C,
    3. Benito A,
    4. Sanz C,
    5. Olalla I,
    6. Fernández-Luna JL
    . Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med 1998;338:564–71.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Spivak JL
    . The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol 2004;41:1–5.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Spivak JL
    . Polycythemia vera: myths, mechanisms, and management. Blood 2002;100:4272–90.
    OpenUrlFREE Full Text
  7. 7.↵
    1. Beer PA,
    2. Green AR
    . Pathogenesis and management of essential thrombocythemia. Hematology Am Soc Hematol Educ Program 2009;621–8.
  8. 8.↵
    1. Finazzi G,
    2. Barbui T
    . How I treat patients with polycythemia vera. Blood 2007;109:5104–11.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Passamonti F,
    2. Cervantes F,
    3. Vannucchi AM,
    4. Morra E,
    5. Rumi E,
    6. Pereira A,
    7. et al.
    A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115:1703–8.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Cervantes F,
    2. Dupriez B,
    3. Pereira A,
    4. Passamonti F,
    5. Reilly JT,
    6. Morra E,
    7. et al.
    New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895–901.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Bacigalupo A,
    2. Soraru M,
    3. Dominietto A,
    4. Pozzi S,
    5. Geroldi S,
    6. Van Lint MT,
    7. et al.
    Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant 2010;45:458–63.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Stewart WA,
    2. Pearce R,
    3. Kirkland KE,
    4. Bloor A,
    5. Thomson K,
    6. Apperley J,
    7. et al.
    The role of allogeneic SCT in primary myelofibrosis: a British society for blood and marrow transplantation study. Bone Marrow Transplant 2010;45:1587–93.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Lacronique V,
    2. Boureux A,
    3. Valle VD,
    4. Poirel H,
    5. Quang CT,
    6. Mauchauffé M,
    7. et al.
    A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997;278:1309–12.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Peeters P,
    2. Raynaud SD,
    3. Cools J,
    4. Wlodarska I,
    5. Grosgeorge J,
    6. Philip P,
    7. et al.
    Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997;90:2535–40.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Ward AC,
    2. Touw I,
    3. Yoshimura A
    . The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 2000;95:19–29.
    OpenUrlFREE Full Text
  16. 16.↵
    1. Mullighan CG,
    2. Zhang J,
    3. Harvey RC,
    4. Collins-Underwood JR,
    5. Schulman BA,
    6. Phillips LA,
    7. et al.
    JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2009;106:9414–8.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Bercovich D,
    2. Ganmore I,
    3. Scott LM,
    4. Wainreb G,
    5. Birger Y,
    6. Elimelech A,
    7. et al.
    Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008;372:1484–92.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Kearney L,
    2. Gonzalez De Castro D,
    3. Yeung J,
    4. Procter J,
    5. Horsley SW,
    6. Eguchi-Ishimae M,
    7. et al.
    Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 2009;113:646–8.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Xiang Z,
    2. Zhao Y,
    3. Mitaksov V,
    4. Kasai Y,
    5. Molitoris A,
    6. Ries RE,
    7. et al.
    Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood 2008;111:4809–12.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Walters DK,
    2. Mercher T,
    3. Gu TL,
    4. O'Hare T,
    5. Tyner JW,
    6. Loriaux M,
    7. et al.
    Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006;10:65–75.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Lee JW,
    2. Kim YG,
    3. Soung YH,
    4. Han KJ,
    5. Kim SY,
    6. Rhim HS,
    7. et al.
    The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 2006;25:1434–6.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Jelinek J,
    2. Oki Y,
    3. Gharibyan V,
    4. Bueso-Ramos C,
    5. Prchal JT,
    6. Verstovsek S,
    7. et al.
    JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005;106:3370–3.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Traer E,
    2. MacKenzie R,
    3. Snead J,
    4. Agarwal A,
    5. Eiring AM,
    6. O'Hare T,
    7. et al.
    Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia 2012;26:1140–3.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Joos S,
    2. Kupper M,
    3. Ohl S,
    4. von Bonin F,
    5. Mechtersheimer G,
    6. Bentz M,
    7. et al.
    Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 2000;60:549–52.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Rosenwald A,
    2. Wright G,
    3. Leroy K,
    4. Yu X,
    5. Gaulard P,
    6. Gascoyne RD,
    7. et al.
    Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198:851–62.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Lenz G,
    2. Wright GW,
    3. Emre NC,
    4. Kohlhammer H,
    5. Dave SS,
    6. Davis RE,
    7. et al.
    Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008;105:13520–5.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Sansone P,
    2. Bromberg J
    . Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 2012;30:1005–14.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Baxter EJ,
    2. Scott LM,
    3. Campbell PJ,
    4. East C,
    5. Fourouclas N,
    6. Swanton S,
    7. et al.
    Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054–61.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. James C,
    2. Ugo V,
    3. Le Couedic JP,
    4. Staerk J,
    5. Delhommeau F,
    6. Lacout C,
    7. et al.
    A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144–8.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Kralovics R,
    2. Passamonti F,
    3. Buser AS,
    4. Teo SS,
    5. Tiedt R,
    6. Passweg JR,
    7. et al.
    A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779–90.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Levine RL,
    2. Wadleigh M,
    3. Cools J,
    4. Ebert BL,
    5. Wernig G,
    6. Huntly BJ,
    7. et al.
    Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387–97.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Zhao R,
    2. Xing S,
    3. Li Z,
    4. Fu X,
    5. Li Q,
    6. Krantz SB,
    7. et al.
    Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005;280:22788–92.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Levine RL,
    2. Gilliland DG
    . Myeloproliferative disorders. Blood 2008;112:2190–8.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Morgan KJ,
    2. Gilliland DG
    . A role for JAK2 mutations in myeloproliferative diseases. Annu Rev Med 2008;59:213–22.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Scott LM,
    2. Tong W,
    3. Levine RL,
    4. Scott MA,
    5. Beer PA,
    6. Stratton MR,
    7. et al.
    JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459–68.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Pietra D,
    2. Li S,
    3. Brisci A,
    4. Rumi E,
    5. Theocharides A,
    6. Ferrari M,
    7. et al.
    Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008;111:1686–9.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Pardanani A,
    2. Lasho TL,
    3. Finke C,
    4. Hanson CA,
    5. Tefferi A
    . Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007;21:1960–3.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Wang YL,
    2. Vandris K,
    3. Jones A,
    4. Cross NC,
    5. Christos P,
    6. Adriano F,
    7. et al.
    JAK2 Mutations are present in all cases of polycythemia vera. Leukemia 2008;22:1289.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Pikman Y,
    2. Lee BH,
    3. Mercher T,
    4. McDowell E,
    5. Ebert BL,
    6. Gozo M,
    7. et al.
    MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Pardanani AD,
    2. Levine RL,
    3. Lasho T,
    4. Pikman Y,
    5. Mesa RA,
    6. Wadleigh M,
    7. et al.
    MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108:3472–6.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Vannucchi AM,
    2. Antonioli E,
    3. Guglielmelli P,
    4. Pancrazzi A,
    5. Guerini V,
    6. Barosi G,
    7. et al.
    Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008;112:844–7.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Beer PA,
    2. Campbell PJ,
    3. Scott LM,
    4. Bench AJ,
    5. Erber WN,
    6. Bareford D,
    7. et al.
    MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008;112:141–9.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Bersenev A,
    2. Wu C,
    3. Balcerek J,
    4. Jing J,
    5. Kundu M,
    6. Blobel GA,
    7. et al.
    Lnk constrains myeloproliferative diseases in mice. J Clin Invest 2010;120:2058–69.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Jamieson CH,
    2. Gotlib J,
    3. Durocher JA,
    4. Chao MP,
    5. Mariappan MR,
    6. Lay M,
    7. et al.
    The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A 2006;103:6224–9.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Ishii T,
    2. Bruno E,
    3. Hoffman R,
    4. Xu M
    . Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 2006;108:3128–34.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Delhommeau F,
    2. Dupont S,
    3. Tonetti C,
    4. Masse A,
    5. Godin I,
    6. Le Couedic JP,
    7. et al.
    Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 2007;109:71–7.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Lu X,
    2. Levine R,
    3. Tong W,
    4. Wernig G,
    5. Pikman Y,
    6. Zamegar S,
    7. et al.
    Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A 2005;102:18962–7.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Jamieson CH,
    2. Barroga CF,
    3. Vainchenker WP
    . Miscreant myeloproliferative disorder stem cells. Leukemia 2008;22:2011–9.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Kota J,
    2. Caceres N,
    3. Constantinescu SN
    . Aberrant signal transduction pathways in myeloproliferative neoplasms. Leukemia 2008;22:1828–40.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Quintas-Cardama A,
    2. Vaddi K,
    3. Liu P,
    4. Manshouri T,
    5. Li J,
    6. Scherle PA,
    7. et al.
    Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115:3109–17.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    1. Wernig G,
    2. Kharas MG,
    3. Okabe R,
    4. Moore SA,
    5. Leeman DS,
    6. Cullen DE,
    7. et al.
    Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008;13:311–20.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Ugo V,
    2. Marzac C,
    3. Teyssandier I,
    4. Larbret F,
    5. Lecluse Y,
    6. Debili N,
    7. et al.
    Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 2004;32:179–87.
    OpenUrlCrossRefPubMed
  53. 53.↵
    1. Tiedt R,
    2. Hao-Shen H,
    3. Sobas MA,
    4. Looser R,
    5. Dimhofer S,
    6. Schwaller J,
    7. et al.
    Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008;111:3931–40.
    OpenUrlAbstract/FREE Full Text
  54. 54.↵
    1. Xing S,
    2. Wanting TH,
    3. Zhao W,
    4. Ma J,
    5. Wang S,
    6. Xu X,
    7. et al.
    Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 2008;111:5109–17.
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    1. Mullally A,
    2. Lane SW,
    3. Ball B,
    4. Megerdichian C,
    5. Okabe R,
    6. Al-Shahrour F,
    7. et al.
    Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010;17:584–96.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Akada H,
    2. Yan D,
    3. Zou H,
    4. Fiering S,
    5. Hutchison RE,
    6. Mohi MG
    . Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010;115:3589–97.
    OpenUrlAbstract/FREE Full Text
  57. 57.↵
    1. Dawson MA,
    2. Bannister AJ,
    3. Gottgens B,
    4. Foster SD,
    5. Bartke T,
    6. Green AR,
    7. et al.
    JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 2009;461:819–22.
    OpenUrlCrossRefPubMed
  58. 58.↵
    1. Liu F,
    2. Zhao X,
    3. Perna F,
    4. Koppikar P,
    5. Abdel-Wahab O,
    6. Harr MW,
    7. et al.
    JAK2 V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell 2011;19:283–94.
    OpenUrlCrossRefPubMed
  59. 59.↵
    1. Quintas-Cardama A,
    2. Kantarjian H,
    3. Cortes J,
    4. Verstovsek S
    . Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 2011;10:127–40.
    OpenUrlCrossRefPubMed
  60. 60.↵
    1. Nussenzveig RH,
    2. Cortes J,
    3. Sever M,
    4. Quintas-Cardama A,
    5. Ault P,
    6. Manshouri T,
    7. et al.
    Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. Int J Hematol 2009;90:58–63.
    OpenUrlCrossRefPubMed
  61. 61.↵
    1. Verstovsek S,
    2. Kantarjian H,
    3. Mesa R,
    4. Pardanani AD,
    5. Cortes-Franco J,
    6. Thomas DA,
    7. et al.
    Safety and efficacy of a JAK1 and JAK2 inhibitor, INCB018424, in myelofibrosis. N Engl J Med 2010;363:1117–27.
    OpenUrlCrossRefPubMed
  62. 62.↵
    1. Verstovsek S,
    2. Mesa RA,
    3. Gotlib J,
    4. Levy RS,
    5. Gupta V,
    6. DiPersio JF,
    7. et al.
    A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799–807.
    OpenUrlCrossRefPubMed
  63. 63.↵
    1. Verstovsek S,
    2. Mesa RA,
    3. Gotlib J,
    4. Levy R,
    5. Gupta V,
    6. DiPersio JF,
    7. et al.
    Long-term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I. Blood 2012;120. Abstract nr 800.
  64. 64.↵
    1. Harrison C,
    2. Kiladjian JJ,
    3. Al-Ali HK,
    4. Gisslinger H,
    5. Waltzman R,
    6. Stalbovskaya V,
    7. et al.
    JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787–98.
    OpenUrlCrossRefPubMed
  65. 65.↵
    1. Cervantes F,
    2. Kiladjian JJ,
    3. Niederwieser D,
    4. Sirulnik A,
    5. Stalbovskaya V,
    6. McQuitty M,
    7. et al.
    Long-term safety, efficacy, and survival findings from comfort-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood 2012;120. Abstract nr 800.
  66. 66.↵
    1. Pardanani A,
    2. Gotlib JR,
    3. Jamieson C,
    4. Cortes JE,
    5. Talpaz M,
    6. Stone RM,
    7. et al.
    Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29:789–96.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    1. Pardanani A,
    2. Gotlib JR,
    3. Jamieson C,
    4. Cortes JE,
    5. Talpaz M,
    6. Stone R,
    7. et al.
    SAR302503: interim safety, efficacy and long-term impact on JAK2 V617F allele burden in a phase I/II study in patients with myelofibrosis. Blood 2011;118. Abstract nr 3838.
  68. 68.↵
    1. Talpaz M,
    2. Jamieson C,
    3. Gabrail NY,
    4. Lebedinsky C,
    5. Neumann F,
    6. Gao G,
    7. et al.
    A phase II randomized dose-ranging study of the JAK2-selective inhibitor SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera MF, or post-essential thrombocythemia MF. Blood 2012;120. Abstract nr 2837.
  69. 69.↵
    1. Pardanani A,
    2. Gotlib J,
    3. Gupta V,
    4. Roberts AW,
    5. Wadleigh M,
    6. Sirhan S,
    7. et al.
    Phase I/II study of CYT387, a JAK1/JAK2 inhibitor for the treatment of myelofibrosis. Blood 2012;120. Abstract nr 178.
  70. 70.↵
    1. Pardanani A,
    2. George G,
    3. Lasho T,
    4. Hogan WJ,
    5. Litzow MR,
    6. Begna K,
    7. et al.
    A phase I/II study of CYT387, an oral JAK-1/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms. Blood 2010;116. Abstract nr 460.
  71. 71.↵
    1. Komrokji R,
    2. Wadleigh M,
    3. Seymour JF,
    4. Roberts AW,
    5. To LB,
    6. Zhu HJ,
    7. et al.
    Results of a phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. Blood 2011;118. Abstract nr 282.
  72. 72.↵
    1. Younes A,
    2. Romaguera J,
    3. Fanale M,
    4. McLaughlin P,
    5. Hagemeister F,
    6. Copeland A,
    7. et al.
    Phase I study of a novel oral janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol 2012;30:4161–7.
    OpenUrlAbstract/FREE Full Text
  73. 73.↵
    1. Koppikar P,
    2. Bhagwat N,
    3. Kilpivaara O,
    4. Manshouri T,
    5. Adli M,
    6. Hricik T,
    7. et al.
    Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012;489:155–9.
    OpenUrlCrossRefPubMed
  74. 74.↵
    1. Wang Y,
    2. Fiskus W,
    3. Chong DG,
    4. Buckley KM,
    5. Natarajan K,
    6. Rao R,
    7. et al.
    Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 2009;114:5024–33.
    OpenUrlAbstract/FREE Full Text
  75. 75.↵
    1. Guerini V,
    2. Barbui V,
    3. Spinelli O,
    4. Salvi A,
    5. Dellacasa C,
    6. Carobbio A,
    7. et al.
    The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F. Leukemia 2009;22:740–7.
    OpenUrl
  76. 76.↵
    1. Baffert F,
    2. Evrot E,
    3. Ebel N,
    4. Roelli C,
    5. Andraos R,
    6. Qian Z,
    7. et al.
    Improved efficacy upon combined JAK1/2 and pan-deacetylase inhibition using ruxolitinib (INC424) and panobinostat (LBH589) in preclinical mouse models of JAK2V617F-driven disease. Blood 2011;118. Abstract nr 798.
  77. 77.↵
    1. Manshouri T,
    2. Estrov Z,
    3. Quintas-Cardama A,
    4. Burger J,
    5. Zhang Y,
    6. Livun A,
    7. et al.
    Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res 2011;71:3831–40.
    OpenUrlAbstract/FREE Full Text
  78. 78.↵
    1. Tefferi A
    . Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128–38.
    OpenUrlCrossRefPubMed
  79. 79.
    1. Pardanani A,
    2. Gotlib J,
    3. Jamieson C,
    4. Cortes J,
    5. Talpaz M,
    6. Stone R,
    7. et al.
    A phase I study of TG101348, a selective JAK2 inhibitor, in myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden. Blood 2009;114. Abstract nr 755.
  80. 80.
    1. Verstovsek S,
    2. Odenike O,
    3. Scott B,
    4. Estrov Z,
    5. Cortes J,
    6. Thomas DA,
    7. et al.
    Phase I dose-escalation trial of SB1518, a novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia/polycythemia vera myelofibrosis. Blood 2009;114. Abstract nr 3905.
  81. 81.
    1. Pardanani A,
    2. Lasho T,
    3. Smith G,
    4. Burns CJ,
    5. Fantino E,
    6. Tefferi A
    . CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009;23:1441–5.
    OpenUrlCrossRefPubMed
  82. 82.
    1. Tyner JW,
    2. Bumm TG,
    3. Deininger J,
    4. Wood L,
    5. Aichberger KJ,
    6. Loriaux MM,
    7. et al.
    CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010;115:5232–40.
    OpenUrlAbstract/FREE Full Text
  83. 83.
    1. Hedvat M,
    2. Huszar D,
    3. Herrmann A,
    4. Gozgit JM,
    5. Schroeder A,
    6. Sheehy A,
    7. et al.
    The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009;16:487–97.
    OpenUrlCrossRefPubMed
  84. 84.
    1. Jiang JK,
    2. Ghoreschi K,
    3. Deflorian F,
    4. Chen Z,
    5. Perreira M,
    6. Pesu M,
    7. et al.
    Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperi din-1-yl)-3-oxopropanenitrile (CP-690,550). J Med Chem 2008;51:8012–8.
    OpenUrlCrossRefPubMed
  85. 85.
    1. Fridman JS,
    2. Scherle PA,
    3. Collins R,
    4. Burn TC,
    5. Li Y,
    6. Li J,
    7. et al.
    Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2010;184:5298–307.
    OpenUrlAbstract/FREE Full Text
Back to top
Clinical Cancer Research: 19 (8)
April 2013
Volume 19, Issue 8

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Email Article
Citation Tools
Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance
Alfonso Quintás-Cardama and Srdan Verstovsek
Clin Cancer Res April 15 2013 (19) (8) 1933-1940; DOI: 10.1158/1078-0432.CCR-12-0284
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement